Paliperidone-Related Sudden Elevation of Plasma D-Dimer Levels

Congchong Wu,Jianbo Lai,Suili Ma,Manli Huang,Shaohua Hu,Yi Xu

DOI: https://doi.org/10.1097/jcp.0000000000001249

2020-01-01

Journal of Clinical Psychopharmacology

Abstract:Wu, Congchong MM; Lai, Jianbo MD; Ma, Suili MB; Huang, Manli MD; Hu, Shaohua MD; Xu, Yi MD Author Information

What problem does this paper attempt to address?

A Case of Hyperpyrexia Associated with Risperidone Microspheres for Injection (II)

Xiangyuan Diao,Dandan Wang,Shengyong Lu,Shaohua Hu,Jianbo Lai

DOI: https://doi.org/10.1097/jcp.0000000000001535

2022-01-01

Journal of Clinical Psychopharmacology

Abstract:Diao, Xiangyuan MS; Wang, Dandan MD; Lu, Shaojia MD; Hu, Shaohua MD; Lai, Jianbo MD Author Information
Plasma Concentrations of Intramuscular Paliperidone Palmitate and the Relationship Between the Dose and Clinical Safety

LI Dan-meng,MI Wei-feng,LI Ling-zhi,WANG Zhi-ren,WANG Yue-chan,ZHANG Hong-yan

DOI: https://doi.org/10.3969/j.issn.1001-6821.2012.08.001

2012-01-01

Abstract:Objective To analyze the plasma concentrations of paliperidone palmitate and the relationship between the dose and clinical safety.Methods Eighteen patients met the DSM-IV diagnosis of schizophrenia received injection of paliperidone palmitate on day 1,8,38 of fix-dose,and every 30 days of flexible-dose.The groups were divided according to the last three actual-given doses.The blood were taken on day 8th,11th,14th,17th,21st,28th,38th,68th,98th,128th,158th and 188th.The plasma concentrations of paliperidone palmitate were detected by HPLC method.The clinical symptom was measured by PANSS on day 1st and 188th.Clinical safety was evaluated by monitoring of adverse events and vital signs,lab tests and extrapyramidal side effects scale.All the data were analyzed by SPSS.Results Seventeen patients completed the project,and were divided into 3 groups: 75 mg eq.(n=5),100 mg eq.(n=9),and 150 mg eq.(n=3).The mean plasma concentrations of each group were(23.42±11.95),(24.52±12.44),(16.92±6.53) ng·mL-1,the peak concentrations reached at day 11th-18th,and the average time was day17th.There were 11 subjects reported totally 17 cases of adverse reactions,which were mild to moderate.Conclusion The steady-state concentrations of paliperidone palmitate have no difference among the groups,while individual differences are significant.And the drug doses are not associated with the adverse reactions.
Paliperidone poisoning and measurable plasma concentrations 2.5 years after last administered dose: A case report

Mariam Nersesjan,Maria Wagner,Kim Peder Dalhoff,Tonny Studsgaard Petersen,Søren Bøgevig,Henrik Horwitz

DOI: https://doi.org/10.1111/bcp.16036

2024-03-08

British Journal of Clinical Pharmacology

Abstract:We report a poisoning with paliperidone palmitate, a once‐monthly, long‐acting injectable antipsychotic. The patient suffered from deep sedation and dystonia. She had been treated with extended release intramuscular paliperidone for several years and had received her last injection 8 days prior to admission. The plasma paliperidone was nearly five times higher than the upper reference range. Paliperidone is a substrate of p‐glycoprotein and we therefore aimed to increase its elimination by inducing p‐glycoprotein through treatment with St John's wort. This seemed to have a limited effect on paliperidone clearance. Plasma concentration levels decreased with time as did the dystonia. All antipsychotic treatment was discontinued after this unfortunate event, and the patient did specifically not receive any prescriptions of paliperidone or risperidone. However, the plasma paliperidone concentration was in the low end of the normal therapeutic range 2.5 years after the last dose of paliperidone was administered, and the patient still had some extrapyramidal symptoms.

pharmacology & pharmacy
The Level of D-Dimer Is Positively Correlated With the Severity of <i>Mycoplasma pneumoniae</i> Pneumonia in Children

Mengyao Li

DOI: https://doi.org/10.3389/fcimb.2021.687391

IF: 6.073

2021-01-01

Frontiers in Cellular and Infection Microbiology

Abstract:Objective Mycoplasma pneumoniae pneumonia (MPP) is an important disease in children. Studies have demonstrated that the levels of D-dimer are elevated in some children with MPP, especially those with thrombotic complications. However, the potential association between MPP and D-dimer remains unclear. In our study, we sought to explore the relationship between the levels of plasma D-dimer and clinical characteristics of MPP patients. Methods Retrospective analysis was conducted on 356 patients who were hospitalized in our hospital for MPP between January 1, 2017, and December 31, 2019. According to the peak value of D-dimer, patients were divided into three groups: the normal group (D-dimer < 0.55 mg/L), the mild-moderately elevated group (D-dimer 0.55-5.5 mg/L) and the severely elevated group (D-dimer > 5.5 mg/L). The demographic and clinical information, radiological findings, laboratory data, and treatments of patients were compared among different groups. Results 106 patients were in the normal group, 204 patients were in the mild-moderately elevated group, and 46 patients were in the severely elevated group. More severe clinical and radiographic manifestations, longer length of fever, hospital stay and antibiotic therapy duration, higher incidences of extra-pulmonary complications, refractory MPP (RMPP), severe MPP (SMPP) were found in the elevated group, when compared with the normal group (P < 0.01). Meanwhile, we found that the percentage of neutrophil (N%) and CD8 (+) lymphocyte (CD8 (+)%), C-reactive protein (CRP), lactate dehydrogenase (LDH), interleukin (IL)-6, IL-10, and interferon-gamma (IFN-gamma) trended higher with increasing D-dimer, whereas the percentage of lymphocyte (L%) and prealbumin (PAB) trended lower (P < 0.01). In addition, the proportions of patients requiring oxygen therapy, glucocorticoid, bronchoscopy, immunoglobulin use, thoracentesis, or ICU admission were significantly higher in the severely elevated group than those in the other two groups (P < 0.01). Correlation analysis showed that N%, L%, CRP, LDH, IL-10, length of fever, length of stay, and length of antibiotic therapy had strong correlations with the level of D-dimer. Conclusions MPP patients with higher levels of D-dimer had more severe clinical manifestations and needed longer duration of treatment, which might be closely related to the severity of lung inflammation after MP infection.
Characteristics of emergency patients with markedly elevated D-dimer levels

Ning Tang,Yinyin Pan,Chao Xu,Dengju Li

DOI: https://doi.org/10.1038/s41598-020-64853-0

2020-05-08

Abstract:Background: Markedly elevated D-dimer levels can occur in emergency patients with various clinical situations, and is likely to indicate the presence of coagulopathy, rapid differential diagnosis was crucial for them. Methods: D-dimer was detected in consecutive 813 patients entering the emergency department of our hospital, for the patients with D-dimer levels above 5.0 µg/mL, the final diagnoses and 28-day mortality were confirmed, and the levels of thrombomodulin (TM), thrombin-antithrombin complex (TAT) and plasmin-antiplasmin complex (PAP) on admission were detected. Results: There were 148 emergency patients with D-dimer levels higher than 5.0 µg/mL mainly due to sepsis, malignancy, trauma, venous thromboembolism (VTE), cerebrovascular accident, and so on. Both of the TM and TAT levels among these diagnoses were significantly different (p < 0.001). The elevated TM (>13.3 TU/mL) had a predictive value of 96.0% for excluding VTE, and the normal TM had a predictive value of 90.4% for excluding sepsis. The overall 28-day mortality of these patients with D-dimer >5.0 ug/mL was 14.2%, the TAT level on admission was independently associated with 28-day mortality (odds ratio 1.014, 95% CI 1.001-1.027, P = 0.030). Conclusions: The medical emergencies associated with markedly elevated D-dimer levels were revealed, specific markers of endothelial dysfunction and thrombin generation measured by automatic analyzer have the potential to distinguish diagnoses and predict outcomes in these patients.
Fatal and life-threatening ADRs associated with paliperidone palmitate: an observational study in the French pharmacovigilance database

D Boels,J Mahé,A Olry,A Citterio-Quentin,J Moragny,P Jolliet

DOI: https://doi.org/10.1080/15563650.2021.1878206

Abstract:Introduction: Paliperidone palmitate (PP), a long-acting intramuscular formulation of paliperidone, has been marketed in Europe within the last 10 years and provides an important treatment option for patients with schizophrenia.Our aim was to describe PP-related adverse drug reactions (ADRs) leading to death or life-threatening events, specifying their main clinical and pharmacological characteristics. Methods: This observational study was a retrospective review of PP-related ADRs in the French pharmacovigilance database between January 1, 2013, and December 31, 2019. Results: Out of 473 PP-related ADRs, we identified 13 deaths and 14 life-threatening events. ADRs were primarily cardiorespiratory (n = 17; 63%). Other symptoms observed were mainly metabolic (n = 4), digestive (n = 4), and neurological (n = 4). Cardiorespiratory symptoms were generally observed within first 6 months after initiation of treatment (11 out of 17 cases), unlike metabolic disorders (all 4 cases 12-21 months after initiation). Cardiac arrests and sudden unexpected deaths occurred 10-14 days after the last PP once-monthly injection (23 cases) or 11-24 days after the last PP three-monthly injection (remaining 4 cases). No PP blood concentration assays were performed for these patients. Discussion: In this study, PP-related ADRs leading to death or life-threatening events mainly presented with cardiorespiratory symptoms and tended to occur in the first 6 months after the initiation of treatment and within postadministration periods aligned with peak plasma PP concentrations. The hypothesis of supratherapeutic drug concentrations following intramuscular PP injection must be raised. Conclusion: PP-related ADRs leading to death or life-threatening events mainly presented with cardiorespiratory symptoms. Cardiac arrests and sudden unexpected deaths following initiation of PP treatment could be due to supratherapeutic drug concentrations. This study highlights the need to monitor blood concentrations of PP.Key pointsAdverse reactions to paliperidone palmitate can lead to death or life-threatening events.It is hypothesized that cardiac arrests and sudden unexpected deaths following initiation of paliperidone palmitate treatment could be due to supratherapeutic drug concentrations.This paper proposes the need to monitor blood concentrations of paliperidone palmitate in future studies.
Prevalence and Outcomes of D-Dimer Elevation in Hospitalized Patients With COVID-19

Jeffrey S. Berger,Dennis Kunichoff,Samrachana Adhikari,Tania Ahuja,Nancy Amoroso,Yindalon Aphinyanaphongs,Meng Cao,Ronald Goldenberg,Alexander Hindenburg,James Horowitz,Sam Parnia,Christopher Petrilli,Harmony Reynolds,Emma Simon,James Slater,Shadi Yaghi,Eugene Yuriditsky,Judith Hochman,Leora I. Horwitz

DOI: https://doi.org/10.1161/atvbaha.120.314872

2020-10-01

Abstract:Objective: To determine the prevalence of D-dimer elevation in coronavirus disease 2019 (COVID-19) hospitalization, trajectory of D-dimer levels during hospitalization, and its association with clinical outcomes. Approach and Results: Consecutive adults admitted to a large New York City hospital system with a positive polymerase chain reaction test for SARS-CoV-2 (severe acute respiratory syndrome coronavirus 2) between March 1, 2020 and April 8, 2020 were identified. Elevated D-dimer was defined by the laboratory-specific upper limit of normal (>230 ng/mL). Outcomes included critical illness (intensive care, mechanical ventilation, discharge to hospice, or death), thrombotic events, acute kidney injury, and death during admission. Among 2377 adults hospitalized with COVID-19 and ≥1 D-dimer measurement, 1823 (76%) had elevated D-dimer at presentation. Patients with elevated presenting baseline D-dimer were more likely than those with normal D-dimer to have critical illness (43.9% versus 18.5%; adjusted odds ratio, 2.4 [95% CI, 1.9–3.1]; P <0.001), any thrombotic event (19.4% versus 10.2%; adjusted odds ratio, 1.9 [95% CI, 1.4–2.6]; P <0.001), acute kidney injury (42.4% versus 19.0%; adjusted odds ratio, 2.4 [95% CI, 1.9–3.1]; P <0.001), and death (29.9% versus 10.8%; adjusted odds ratio, 2.1 [95% CI, 1.6–2.9]; P 2000 ng/mL had the highest risk of critical illness (66%), thrombotic event (37.8%), acute kidney injury (58.3%), and death (47%). Conclusions: Abnormal D-dimer was frequently observed at admission with COVID-19 and was associated with higher incidence of critical illness, thrombotic events, acute kidney injury, and death. The optimal management of patients with elevated D-dimer in COVID-19 requires further study.
Complete Atrioventricular Block Associated with Dapsone Therapy: a Rare Complication of Dapsone-Induced Hypersensitivity Syndrome

K. J. Zhu,F. T. He,N. Jin,J. X. Lou,H. Cheng

DOI: https://doi.org/10.1111/j.1365-2710.2008.00991.x

2009-01-01

Journal of Clinical Pharmacy and Therapeutics

Abstract:Dapsone is still widely used for a range of infectious and inflammatory diseases. A potential severe side-effect, known as dapsone-induced hypersensitivity syndrome (DHS), may occur. DHS is characterized by fever, skin rashes, lymphadenopathy and multiorgan dysfunction manifesting as hepatitis, cholangitis, pneumonitis, colitis, thyroiditis and myocarditis. However, DHS-associated complete atrioventricular block has not previously been reported. We describe here a 45-year-old Chinese woman who developed DHS after 5 weeks of dapsone therapy for pustular palmoplantar psoriasis. In addition to typical DHS symptoms, she experienced several episodes of syncope as a result of complete atrioventricular block which was successfully reversed with a permanent pacemaker implantation.
The Clinical Significance of D-dimer in Systemic Lupus Erythematosus

Chun Li,Rong Mu,Li-min Ren,Wen-qiang Fan,Chang-ji Ren,Zhan-guo Li

DOI: https://doi.org/10.3760/cma.j.issn.0578-1426.2010.12.013

2010-01-01

Abstract:Objective To investigate the clinical significance of D-dimer in systemic lupus erythematosus (SLE). Methods The study group comprised 261 SLE patients who were admitted in ward from 2005 to 2008 in Peking University People's Hospital Collect the clinical data to investigate the clinical significance of D-dimer. Results ( 1 ) The D-dimer levels of 56 patients were increased due to coexist reduced renal function, infections, disseminated intravascular coagulation ( DIC), liver disorders, pregnancy and injury. With the exception of above patients, 142 ( 69. 3 ) patients were increased in total 205 patients. (2)The level of D-dimer was positively correlated with SLE disease activity index( SLEDAI ) score ( r =0. 598,P =0. 000), and was associated with anti-dsDNA antibody, ESR, C-reactive protein(CRP) and complement C3 and C4. (3)D-dimer level was associated with important organ involvement. (4)All patients with thrombosis had increased D-dimer, but patients without thrombosis had normal or increased D-dimer levels. Conclusion The level of D-dimer elevates in patients with active disease or important organ involvement , it can not identify thrombosis. All patients with thrombosis had increased D-dimer levels.
Long-acting injectable paliperidone palmitate induced severe cutaneous allergic reaction in a patient with first episode delusional disorder tolerating oral paliperidone regimen: a case report

Natasa Borojevic,Midya Dawud,Junhua Xiao,Yang Yun

DOI: https://doi.org/10.1186/s12888-022-04347-7

IF: 4.144

2022-11-26

BMC Psychiatry

Abstract:Paliperidone is a second-generation antipsychotic agent that is effective in the treatment of schizophrenia and schizoaffective disorder as well as an adjunct to mood stabilizers and antidepressants for bipolar and depressive disorders. Paliperidone is available in both oral and injection forms. Here we report an unexpected case of cutaneous allergic reaction induced by paliperidone long-acting injection (LAI) following oral tolerance.

psychiatry
D-dimer Surge and Coagulation Disorders in COVID-19 Related Pneumonia Patients with Cardiac Injury

Xingtong Wang,Beibei Du,Jia Li,Shunan Wang,Xiuxiu Wang,MengYuan Guo,Bo Yang,Daoyuan Si,Ou Bai

DOI: https://doi.org/10.1097/md.0000000000021513

IF: 1.6

2020-01-01

Medicine

Abstract:Abstract Background: Cardiac injury and coagulation disorders have been two increasing concerns in the management of patients with severe coronavirus disease (COVID-19). Coagulation disorders in COVID-19 patients with cardiac injury have not been characterized. Methods: We analyzed the data of five COVID-19 patients with cardiac injury who had D-dimer surge (defined as a rapid increase in the D-dimer level in 72 h, from <5–21 μg/mL) during hospitalization, which were extracted from a registered retrospective study (ChiCTR2000031301). Clinical data and data on changes in coagulation parameters were collected, verified, and characterized. Results: Among these five patients, four had pre-existing cardiovascular or cerebrovascular diseases. D-dimer surge was accompanied with prolonged prothrombin time (PT) and reduced platelet count (PLT) and fibrinogen level. Three patients had an ISTH DIC score of 5 and met the criteria for overt DIC. All five patients needed invasive ventilation support and were incubated 0 to 6 days after the first D-dimer upper reference limit (URL) was reached. All five patients died within 10 days after the first D-dimer URL was reached. All five patients had observed D-dimer URL results 1 to 3 days before death. Conclusion: D-dimer surge in COVID-19 patients with cardiac injury surely leads to worse in-hospital outcome. D-dimer surge and concomitant DIC can be the leading causes of in-hospital death. Pre-existing cardiovascular or cerebrovascular diseases might pose a higher risk for developing these coagulation disorders. These findings can serve as hypothesis generating and need further clinical trials to confirm.
Severe acute urticaria is associated with elevated plasma levels of D‐dimer

Lele Chen,Qiuyang Xu,Jingjing Liu,Zhiming Li,Jingying Wang

DOI: https://doi.org/10.1111/1346-8138.17024

IF: 3.468

2023-11-12

The Journal of Dermatology

Abstract:Evaluation of the disease severity of acute urticaria (AU) is essential for adequate treatment of patients. However, there are no reliable biomarkers for such an evaluation. In our department, we observed patients with severe AU having elevated plasma D‐dimer levels. Thus, the objective of this study was to investigate the elevated D‐dimer levels in patients with severe AU in more detail. One hundred and thirty‐nine hospital patients diagnosed with severe AU were enrolled. Clinical laboratory data were collected from electronic medical records. One hundred and seventeen of the patients presented with elevated plasma D‐dimer levels. Compared to the normal group, the elevated group had a significantly higher proportion of patients who were female, younger, febrile, and had a shorter prehospital time (P

dermatology
D-dimer: old dogmas, new (COVID-19) tricks

Giuseppe Lippi,François Mullier,Emmanuel J Favaloro

DOI: https://doi.org/10.1515/cclm-2022-0633

2022-07-14

Abstract:D-dimer is a fibrin degradation product encompassing multiple cross-linked D domains and/or E domains present in the original fibrinogen molecule, whose generation is only theoretically possible when hemostasis and fibrinolysis pathways are concomitantly activated. D-dimer measurement has now become a pillar in the diagnosis/exclusion and prognostication of venous thromboembolism (VTE) and disseminated intravascular coagulation (DIC), when incorporated into validated clinical algorithms and especially using age-adjusted diagnostic thresholds. Although emerging evidence is also supporting its use for predicting the duration of anticoagulant therapy in certain categories of patients, the spectrum of clinical applications is constantly expanding beyond traditional thrombotic pathologies to the diagnosis of acute aortic dissection, acute intestinal ischemia and cerebral venous thrombosis among others, embracing also clinical management of coronavirus disease 2019 (COVID-19). Recent findings attest that D-dimer elevations are commonplace in patients with severe acute respiratory syndrome (SARS-CoV-2) infection (especially in those with thrombosis), its value predicts the clinical severity (up to death) of COVID-19 and remains more frequently increased in COVID-19 patients with post-discharge clinical sequelae. Further, D-dimer-based anticoagulant escalation may be associated with a lower risk of death in patients with severe SARS-CoV-2 infection and, finally, D-dimer elevation post-COVID-19 vaccination mirrors an increased risk of developing vaccine-induced thrombocytopenia and thrombosis (VITT).
Increased levels of plasma D-dimer in the course of Henoch-Schönlein purpura

Bernard Zajadacz,Artur Juszkiewicz

Abstract:Three cases of Henoch-Schönlein purpura (HSP) with elevated plasma D-dimer levels are described. In one case of acute course HSP we observed the beneficial influence of plasma and nadroparine treatment on the course of disease. In two cases plasma D-dimer increase did not correlate with severity of the disease. The possibility of coagulation disturbances in HSP with D-dimer rise (as well as decrease of plasma factor XIII and platelets described in relevant literature) should be taken into consideration. These results suggest presence of mild intravascular clotting process in course of the disease. However, we were not able to clarify the pathogenesis of the high D-dimer serum concentration in HSP. Thus, it is suggested that further research on the discussed condition should be conducted.
The Prognostic Value of D-Dimer in Patients with Acute Myocardial Infarction: A Retrospective Longitudinal Cohort Study in Taiwan

Zong-Yu Yu,Po-Kai Chan,Tzu-Chiao Lin,Yuan Hung,Fang-Han Yu,Wei-Shiang Lin,Shu-Meng Cheng,Wen-Yu Lin

DOI: https://doi.org/10.6515/ACS.202405_40(3).20240126A

Abstract:Background: Serum D-dimer level has been associated with worsening outcomes in patients with acute myocardial infarction. This study aimed to explore the association between serum D-dimer level and clinical outcomes in Taiwanese patients with acute myocardial infarction. Methods: We analyzed Tri-Service General Hospital-Coronary Heart Disease registry data related to patients with acute myocardial infarction who were admitted between January 2014 and December 2018. A total of 748 patients were enrolled and categorized into high (≥ 495 ng/ml) and low (< 495 ng/ml) D-dimer groups. The primary endpoint was in-hospital mortality, and secondary endpoints were post-discharge mortality and post-discharge major adverse cardiovascular events. Results: Overall, 139 patients died, with 77 from cardiovascular causes and 62 from non-cardiovascular causes. In-hospital mortality was higher in the high D-dimer group than in the low D-dimer group. Among the patients alive at discharge, those with a high D-dimer level had higher cardiovascular mortality and future major adverse cardiovascular events than those with a low D-dimer level. Multivariate Cox regression analysis revealed that higher serum D-dimer levels were significantly associated with higher risks of in-hospital mortality [hazard ratio (HR) = 1.11; 95% confidence interval (CI), 1.06-1.16, p < 0.001], subsequent cardiovascular mortality after discharge (HR = 1.15; 95% CI, 1.08-1.22, p < 0.001), and major adverse cardiovascular events (HR = 1.10; 95% CI, 1.04-1.16, p < 0.001). Conclusions: This is the first study in Taiwan to demonstrate that a higher baseline serum D-dimer level was independently associated with higher risks of in-hospital mortality, post-discharge mortality, and major adverse cardiovascular events in patients with acute myocardial infarction.
High plasma D-dimer levels correlate with ictal infarction and poor outcomes in spontaneous subarachnoid hemorrhage

Hitoshi Kobata,Akira Sugie,Adam Tucker,Gemmalynn Sarapuddin,Hitomi Kimura,Hitoshi Takeshita,Munenori Morihara,Makiko Kawakami

DOI: https://doi.org/10.1101/2024.05.26.24307957

2024-05-27

Abstract:BACKGROUND: Early brain injury (EBI) is the leading cause of poor outcomes in patients with spontaneous subarachnoid hemorrhage (sSAH). Plasma D-dimer levels and acute cerebral ischemia have been highlighted as relevant findings in EBI; however, their correlation has not been substantially investigated. METHODS: This retrospective, single-center cohort study was conducted at a tertiary emergency medical center from January 2004 to June 2022. Consecutive patients with sSAH who presented within 12 h of SAH ictus and underwent magnetic resonance imaging within 3 days were included. We assessed the correlation of plasma D-dimer levels with acute ischemic lesions detected on the diffusion-weighted images (DWI) and the clinical characteristics of patients. RESULTS: Among 402 eligible patients (mean age, 63.5 years; 62.7% women; median time from onset to arrival, 45.5 min), 140 (34.8%) had acute ischemic lesions. Higher plasma D-dimer levels linearly correlated with worse neurological grades, more severe SAH on initial CT, acute ischemic lesions, and poor outcomes, except for patients with neurogenic stunned myocardium. In the multivariate analysis, acute ischemic lesions were significantly associated with worse neurological grades, higher plasma D-dimer levels, bilateral loss of light reaction, and advanced age. The receiver operating characteristic curve analysis showed D-dimer levels as excellent predictors for acute ischemic lesions (area under the curve [AUC], 0.897; cut-off value, 5.7 μg/mL, p <0.0001) and unfavorable outcomes (AUC, 0.786; cut-off value, 4.0 μg/mL, p <0.0001). CONCLUSIONS: High plasma D-dimer levels correlated with the appearance of acute ischemic lesions on DWI and were dose-dependently associated with worse neurological grades, more severe hemorrhage, and worse outcomes. Plasma D-dimer levels provide a valuable perspective on various issues in the acute phase of sSAH.
Efficacy and safety of flexibly dosed paliperidone palmitate in Chinese patients with acute schizophrenia: an open-label, single-arm, prospective, interventional study.

Tianmei Si,Kerang Zhang,Jisheng Tang,Maosheng Fang,Keqing Li,Jianmin Zhuo,Yu Feng

DOI: https://doi.org/10.2147/NDT.S81760

IF: 2.989

2015-01-01

Neuropsychiatric Disease and Treatment

Abstract:This open-label, single-arm, multicenter, 13-week, prospective study explored the efficacy, safety, and tolerability of paliperidone palmitate (150 milligram equivalents [mg eq] [day 1], 100 mg eq [day 8], both deltoid injections; 75-150 mg eq, deltoid/gluteal injection) in Chinese patients with acute schizophrenia (Positive and Negative Syndrome Scale [PANSS] total score ≥70), who previously had unsatisfactory therapeutic effect following oral antipsychotic treatment (without washout period). Primary efficacy endpoint was percentage of patients with ≥30% improvement in the PANSS total score at the end of 13 weeks. Secondary efficacy endpoints included change from baseline to end of week 13 in PANSS total score, PANSS subscale scores, Marder factor scores, Clinical Global Impressions-Severity score, and Personal and Social Performance Scale scores. Overall, 477/610 enrolled patients (full analysis set, 78.2%) completed the study (men: 55.1%; women: 44.9%; mean age: 31.5 years). Total, 443/610 (72.6%, full analysis set) patients achieved primary endpoint (mean [standard deviation] change from baseline: -30.9 [19.51]). All secondary endpoints demonstrated significant improvement at the end of 13 weeks. One death occurred during this acute phase. The most common (>5%) treatment-emergent adverse events were extrapyramidal disorders (8.4%). The efficacy and safety data are consistent with other short-term, placebo-controlled studies of paliperidone palmitate conducted in similar populations.
The Relationship Between Serum D-dimer and In-Hospital Adverse Events in Patients with Acute Myocarditis

陈意浓,李青,于璐瑶,朱龙洋,王喆,焦思琪,杨亚柳,闫梦雯,张丽芳,李佳慧,吴文静,孙艺红

DOI: https://doi.org/10.3760/cma.j.issn.1671-0282.2022.11.010

2022-01-01

Abstract:Objective:To investigate the predictive value of serum D-dimer combined with myocardial injury markers on admission for early identification of high-risk patients with acute myocarditis.Methods:Patients hospitalized for acute myocarditis in China-Japan Friendship Hospital were retrospectively enrolled from 2010 to 2021. Patients were divided into the high D-dimer level group and low D-dimer level group according to the median value of D-dimer measured by immunoturbidimetry within 24 h of admission. In-hospital adverse events were defined as death, cardiogenic shock, malignant ventricular arrhythmia and new-onset heart failure. Multivariate logistic analysis was used to explore the independent predictors of in-hospital adverse events, and receiver operating characteristic curve was used to evaluate the predictive value.Results:A total of 106 patients were analyzed, including 52 high level D-dimer patients and 54 low level D-dimer patients, with an average age of (36±16) years, and 62.3% were male. Compared with the low D-dimer level group, patients in the high D-dimer level group had lower mean systolic blood pressure [(114±21) mmHg vs. (121±14) mmHg] and diastolic blood pressure [(71±13) mmHg vs. (76±10) mmHg], higher heart rate [(97±26) beats/min vs. (79±15) beats/min], higher C-reactive protein levels [6.82 (1.61, 20.05) mg/dL vs. 1.30 (0.13, 8.93) mg/dL] and creatinine levels [86.95 (67.63, 117.83) μmol/L vs. 68.80 (60.18, 81.93) μmol/L] on admission. The proportion of patients having QRS interval >120 ms on electrocardiogram was higher in high D-dimer level group (25.0% vs. 7.4%). There was no significant difference in patients with positive myocardial injury biomarkers between the two groups. The incidence of in-hospital adverse events was higher in the high D-dimer level group (67.3% vs. 22.2%, P<0.001). Multivariate logistic analysis showed that serum D-dimer levels and elevated myocardial injury markers on admission were independently associated with in-hospital adverse events. The area under the curve (AUC) of elevated serum D-dimer level on admission for predicting in-hospital adverse events was 0.781 (95% CI: 0.690-0.873), the sensitivity was 74.5%, and the specificity was 71.2%. When combined with positive cardiac biomarkers, the AUC was 0.831 (95% CI: 0.752-0.910) with a sensitivity of 80.9% and a specificity of 78.0%. Conclusions:Elevated D-dimer level on admission can predict the risk of in-hospital adverse events in patients with acute myocarditis. The combination of cardiac injury biomarkers can improve the predictive value.
Associations of D-Dimer on Admission and Clinical Features of COVID-19 Patients: A Systematic Review, Meta-Analysis, and Meta-Regression

Runzhen Zhao,Zhenlei Su,Andrey A. Komissarov,Shan-Lu Liu,Guohua Yi,Steven Idell,Michael A. Matthay,Hong-Long Ji

DOI: https://doi.org/10.3389/fimmu.2021.691249

IF: 7.3

2021-05-07

Frontiers in Immunology

Abstract:Background Dynamic D-dimer level is a key biomarker for the severity and mortality of COVID-19 (coronavirus disease 2019). How aberrant fibrinolysis influences the clinical progression of COVID-19 presents a clinicopathological dilemma challenging intensivists. Methods We performed meta-analysis and meta regression to analyze the associations of plasma D-dimer with 106 clinical variables to identify a panoramic view of the derangements of fibrinolysis in 14,862 patients of 42 studies. There were no limitations of age, gender, race, and country. Raw data of each group were extracted separately by two investigators. Individual data of case series, median and interquartile range, and ranges of median or mean were converted to SDM (standard deviation of mean). Findings The weighted mean difference of D-dimer was 0.97 μg/mL (95% CI 0.65, 1.29) between mild and severe groups, as shown by meta-analysis. Publication bias was significant. Meta-regression identified 58 of 106 clinical variables were associated with plasma D-dimer levels. Of these, 11 readouts were negatively related to the level of plasma D-dimer. Further, age and gender were confounding factors. There were 22 variables independently correlated with the D-dimer level, including respiratory rate, dyspnea plasma K + , glucose, SpO2, BUN (blood urea nitrogen), bilirubin, ALT (alanine aminotransferase), AST (aspartate aminotransferase), systolic blood pressure, and CK (creatine kinase). Interpretation These findings support elevated D-dimer as an independent predictor for both mortality and complications. The identified D-dimer-associated clinical variables draw a landscape integrating the aggregate effects of systemically suppressive and pulmonary hyperactive derangements of fibrinolysis, and the D-dimer-associated clinical biomarkers, and conceptually parameters could be combined for risk stratification, potentially for tracking thrombolytic therapy or alternative interventions.

immunology
A Case of False Decrease of Plasma D-Dimer

Minggang Lu,Liangfeng Hu,Lihong Zhang,Ye Yang

DOI: https://doi.org/10.7754/Clin.Lab.2024.240223

2024-07-01

Abstract:Background: D-dimer, a specific product of cross-linked fibrin degradation, is of great clinical value in the early diagnosis of thrombotic diseases and in monitoring the efficacy of thrombolysis; therefore, the accuracy of D-dimer test results is crucial. Methods: This article reports a case of a patient with disseminated intravascular coagulation (DIC) who experienced a false decrease in D-dimer due to the hook effect. Results: The three D-dimer test results for DIC patients were 1.09 mg/L, 0.93 mg/L, and 1.43 mg/L. After sample dilution, the results were: first time (1:128) 842.24 mg/L, second time (1:128) 1,505.28 mg/L, third time (1:32) 415.68 mg/L. There was a significant difference in the three test results before and after dilution, because the D-dimer concentration was too high, exceeding the detection range and causing the hook effect, which falsely lowered the D-dimer value. Conclusions: When the D-dimer value of DIC patients does not match the clinical situation, the possibility of the hook effect should be considered, and the false decrease can be ruled out by the sample dilution method. In this way, accurate clinical results can be obtained to avoid delaying the diagnosis and treatment of DIC patients.

Paliperidone-Related Sudden Elevation of Plasma D-Dimer Levels

A Case of Hyperpyrexia Associated with Risperidone Microspheres for Injection (II)

Plasma Concentrations of Intramuscular Paliperidone Palmitate and the Relationship Between the Dose and Clinical Safety

Paliperidone poisoning and measurable plasma concentrations 2.5 years after last administered dose: A case report

The Level of D-Dimer Is Positively Correlated With the Severity of <i>Mycoplasma pneumoniae</i> Pneumonia in Children

Characteristics of emergency patients with markedly elevated D-dimer levels

Fatal and life-threatening ADRs associated with paliperidone palmitate: an observational study in the French pharmacovigilance database

Prevalence and Outcomes of D-Dimer Elevation in Hospitalized Patients With COVID-19

Complete Atrioventricular Block Associated with Dapsone Therapy: a Rare Complication of Dapsone-Induced Hypersensitivity Syndrome

The Clinical Significance of D-dimer in Systemic Lupus Erythematosus

Long-acting injectable paliperidone palmitate induced severe cutaneous allergic reaction in a patient with first episode delusional disorder tolerating oral paliperidone regimen: a case report

D-dimer Surge and Coagulation Disorders in COVID-19 Related Pneumonia Patients with Cardiac Injury

Severe acute urticaria is associated with elevated plasma levels of D‐dimer

D-dimer: old dogmas, new (COVID-19) tricks

Increased levels of plasma D-dimer in the course of Henoch-Schönlein purpura

The Prognostic Value of D-Dimer in Patients with Acute Myocardial Infarction: A Retrospective Longitudinal Cohort Study in Taiwan

High plasma D-dimer levels correlate with ictal infarction and poor outcomes in spontaneous subarachnoid hemorrhage

Efficacy and safety of flexibly dosed paliperidone palmitate in Chinese patients with acute schizophrenia: an open-label, single-arm, prospective, interventional study.

The Relationship Between Serum D-dimer and In-Hospital Adverse Events in Patients with Acute Myocarditis

Associations of D-Dimer on Admission and Clinical Features of COVID-19 Patients: A Systematic Review, Meta-Analysis, and Meta-Regression

A Case of False Decrease of Plasma D-Dimer